The cumulative sales of Biktarvy amounted to ￦60 billion

It has the shortest market share in the domestic HIV market

Global sales amounted to ￦8 trillion

It is excellent in effectiveness and safety

Gilead Science's Biktarvy dominated the AIDS tx market around the world, including Korea, two years after its launch.

 

Biktarvy consists of Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate as Gilead's HIV treatment.

 

Compared to conventional treatments, the effectiveness and safety are improved, the expression rate of resistance is low, the pill size is small, and it can be administered regardless of meal.

 

After obtaining approval from the MFDS in January 2019, Biktarvy entered the market in earnest by applying benefit in July of the same year.

 

According to IQVIA, a pharmaceutical market research firm, Biktarvy's sales increased to 4.6 billion won in the first quarter of its launch.

 

In 2020, quarterly sales increased to 6.6 billion won, 7.9 billion won, and 9.8 billion won, respectively.

 

It recorded 10.5 billion won in the first quarter of this year.

 

Until the second quarter of this year, cumulative 24-month sales amounted to 59 billion won.

 

In June 2019, just before the launch of Biktarvy, the HIV market had Genvoya and GSK's Triumeq.

 

Genvoya and Triumeq accounted for 44.3% of cumulative market share over the year.

 

Biktarvy recorded a cumulative market share of 19.4% over a year in June 2020, one year after its launch.

 

In June this year, the market share was 38.3%, surpassing both Triumeq and Genvoya.

 

As a result, Biktarvy topped the domestic HIV treatment market in the shortest time.

 

This is because at the time of introduction in Korea, the time required from permission to notification was reduced to one-fifth, and permission and insurance benefit registration were completed in about 100 days.

 

Gilead successfully made a replacement from Genvoya to Biktarvy.

 

Biktarvy has already been a blockbuster in the global HIV treatment market.

 

It posted about 8 trillion won in global sales last year, up 53.1% from about 5 trillion won a year earlier.

 

Biktarvy ranked ninth in the world's most sold medicine last year.

 

This is the first and only HIV treatment to be ranked in the top 10 in sales.

 

Leading global HIV trends is analyzed as a factor in sales.

 

Even in the COVID-19 pandemic, Biktarvy is recommended as a primary treatment.

 

The BHIVA issued guidelines for ART to be applied to HIV-infected people in August last year, recommending Biktarvy as the only initial treatment drug among HIV treatments.

 

It emphasized, "HIV infected people have a higher risk of COVID-19 death than the general population, so they should receive ART treatment, and it is important to use drugs that can effectively control the virus." Another HIV treatment trend is RapIT (Rapid Initation of Treatment).

 

RapIT recommends major guidelines such as the WHO and IAS that treatment begins quickly within up to seven days of HIV diagnosis.

 

Unlike other treatments, Biktarvy is considered a drug that meets the rapid treatment trend because it does not contain ABC and does not limit the virus level or CD4+ level of infected people.

 

The DHHS recommends that acute and new HIV-infected people can start treatment through Biktarvy before confirming the results of genetic drug resistance tests.

 

Biktarvy is the first and only HIV treatment to contain symptoms and emotional conditions that patients feel in their daily lives.

 

In the PRO, patients evaluated that Biktarvy improved nausea, vomiting, sleep disorders, and fatigue compared to existing treatments, so patients' satisfaction was high.

 

An official from Gilead Science Korea said, "Biktarvy has become the world's most prescribed HIV treatment, proving its strong and long-lasting virus suppression effect and long-term safety through the combination of upgraded integrated enzyme inhibitors and proven effective TAF drugs." He also said, "We will provide a good treatment experience for patients in need of drug switching and strengthen patient-centered marketing activities."